Abstract: Autophagy is a vesicle and lysosome-mediated degradative pathway that is essential for protein homeostasis and cell health. In particular, compared to nonneuronal cells, neurons are dependent on high basal autophagy for survival. There is emerging agreement that defects in autophagy are likely to contribute to the neurodegenerative processes in numerous diseases, including Alzheimer's disease (AD). Autophagy-lysosome defects occur early in the pathogenesis of AD and have been proposed to be a significant contributor to the disease process. Given the fact that autophagy deficits are likely major contributors to the etiology of AD, the focus of this review will be on recent studies that support a role for autophagy deficits in AD.
Introduction
Alzheimer's disease (AD) is the most common form of dementia, which impacts more than 35 million people worldwide. The incidence of the disease doubles every 5 years after 65 years of age, with the diagnosis of 1275 new cases per year per 100 000 persons older than 65 years of age (Querfurth and Laferla, 2010) . This disease involves a progressive loss of synapses in the cerebral cortex and hippocampus leading to impaired memory and the deterioration of cognitive functions (Dekosky and Scheff, 1990; Scheff et al., 2006) . Although extracellular aggregates of the peptide Aβ (the amyloid plaques) and intraneuronal accumulations of abnormally processed τ (the neurofibrillary tangles) define AD, it is clear that deficits in the autophagy-lysosome pathway likely precede the formation of these pathological hallmarks (Nixon and Yang, 2011) . Deficits in this pathway manifest as defective autophagy, the major degradative pathway of neurons (Boland et al., 2008) , which likely contributes to the formation of the classic AD hallmarks of amyloid plaques and neurofibrillary tangles and the resulting cognitive decline. Given the fact that autophagy deficits are likely major contributors to the etiology of AD, the focus of this review will be on recent studies that support a role for autophagy deficits in AD and suggest possible sites of therapeutic intervention. We will begin with an overview of the normal functions of autophagy, the molecular pathways involved in this process, and the factors related to the reduction and induction of autophagy before discussing the role of defects in autophagy in AD pathology.
Normal functions of autophagy
The autophagy-lysosome system is a complex chain of events leading to the clearance of misfolded or damaged proteins and dysfunctional organelles as well as contributing to membrane biogenesis and vesicular transport (Ichimura and Komatsu, 2010; Kodiha and Stochaj, 2011) . This cellular machinery is induced by a variety of signals, including nutrient starvation, oxidative stress, and neuronal excitotoxicity (Ichimura and Komatsu, 2010; Murrow and Debnath, 2013) . Via this process, cells can degrade damaged or unessential components and restore substrates for energy and cellular remodeling, which maintains cellular homeostasis . This process is essential to clear long-lived proteins, aggregated protein, and damaged organelles (Murrow and Debnath, 2013) .
There are three forms of autophagy: (a) Chaperone-mediated autophagy (CMA) involves cytoplasmic proteins being selectively delivered into the lysosome through the recognition of specific motifs that are biochemically related to the pentapeptide KFERQ. First, CMA substrates are recognized in the cytoplasm by the heat shock cognate protein of 70 kDa (Hsc70). The chaperone-KFERQ-containing protein complex then binds lysosome-associated membrane protein (LAMP)-2A receptors on the lysosomal membrane and translocates the target proteins into the lysosomes for degradation (Fred Dice, 1990; Bejarano and Cuervo, 2010; Kaushik et al., 2011 ; reviewed by Majeski and Fred Dice, 2004; Bejarano and Cuervo, 2010; Kaushik et al., 2011) . (b) Microautophagy in which the cytoplasmic components are directly engulfed by the lysosome (reviewed by Li et al., 2012) . (c) Macroautophagy in which hierarchically ordered activity of autophagy-related (ATG) proteins leads to the cytoplasmic components being engulfed by autophagic vacuoles (AVs) and degraded by proteases after fusion with lysosomes Jisun et al., 2012; Tung et al., 2012) . In addition to this bulk autophagy pathway, cargos can be selectively targeted to the autophagy machinery by specific autophagy receptor (Johansen and Lamark, 2011) . Macroautophagy, which we will refer to by the general term autophagy, is the focus of this review. It is considered the predominant contributor to the overall autophagy rate under most conditions. Its role as a causative or protective factor and even as a consequence of AD process is not clear yet.
Stages of autophagy
The initial step of autophagy is the appearance of a small membrane sac followed by its elongation. The elongated membrane, called the isolation membrane/phagophore, engulfs part of the cytoplasm and becomes a doublemembrane structure of multiple proteins, including microtubule-associated light chain 3-II (LC3-II), termed the autophagosome, through the fusion of the two ends of the membrane (Ichimura and Komatsu, 2010; Nixon and Yang, 2011) .
The maturation processes of the autophagosome include fusion with lysosomes or other mature AVs, which results in the acidification and acquisition of proteolytic enzymes that degrade the inner membrane of the autophagosome, together with the contents. Additionally, endocytosed constituents can enter the autophagic pathway when endosomes fuse with autophagosomes to generate an amphisome (Ichimura and Komatsu, 2010; . The stages are shown in Figure 1 .
Most of the steps in this process require the cytoskeletal network proteins such as dynein and LC3-II (an autophagosomal membrane protein and a marker of autophagosomes; Kabeya et al., 2000) , which are associated with microtubule transport . Although autophagic pathways appear to nonselectively engulf cytosolic molecules, they can also selectively trap certain cargoes by the association between LC3 and a cargo receptor such as p62; neighbor of BRCA1, breast cancer earlyonset 1 (NRB1); or nuclear dot protein 52 (NDP52; Bjørkøy et al., 2005; Kirkin et al., 2009a; Jo et al., 2014) . p62 and NRB1 are both multifunctional proteins that highly interact with ubiquitinated and misfolded proteins and the ATG8 family (Bjørkøy et al., 2005; Pankiv et al., 2007; Kirkin et al., 2009a) , which is critical for autophagosomal formation (Kabeya et al., 2000) . There is less information about NDP52. This molecule functions as an autophagic adaptor for the selective degradation of Toll/IL-1 receptor homology domain-containing adaptor inducing IFN-β and TNF receptor-associated factor 6 in the periphery (Inomata et al., 2012) . It was suggested that it plays a role in autophagosome maturation by docking with myosin VI together with T6BP and optineurin ( Tumbarello et al., 2012) . Recent studies indicated that NDP52 is a downstream facilitator of nuclear factor erythroid 2-related factor 2-mediated phosphorylated τ degradation by autophagy (Jo et al., 2014) .
Regulation of autophagy

Mammalian target of rapamycin-dependent signaling pathway
Mammalian target of rapamycin (mTOR) is a kinase that is activated in the presence of growth factors and abundant cellular nutrients such as amino acids and inhibits the initiation step of autophagy by the phosphorylation of ATG13, preventing its association with UNC-51-like kinase and focal adhesion kinase family interacting protein of 200-kDa (FIP200) recruitment. Starvation results in mTOR inhibition that activates phosphatases and partial dephosphorylation of ATG13 leading to autophagosomal formation (Kundu, 2011; Jisun et al., 2012) . mTOR complex 1 (mTORC1) is a complex that mediates the classic functions of mTOR (Kim et al., 2002; Hay and Sonenberg, 2004) . Recently, Rag GTPases, which are also members of the Ras family of GTP-binding proteins, were shown to be amino acid-specific regulators of the mTORC1 pathway. Amino acids promote the translocation of mTORC1 -in a Rag-dependent fashion -to the lysosomal surface (Sancak et al., 2010; Jisun et al., 2012) . mTORC1 regulates cell growth by the coordination of upstream signals from growth factors. Tuberous sclerosis complex 1 (TSC1) and TSC2 proteins form a tumor suppressor complex that transmits growth factor and energy signals to mTORC1 by regulating the GTP-loading state of Ras homolog enriched in brain (Rheb), a Ras-related GTPbinding protein. When bound to GTP, Rheb interacts with and activates mTORC1 (Sancak et al., 2010) . Upon growth factor depletion, the p110β catalytic subunit of the class IA phosphoinositide 3-kinases (PI3Ks) dissociates from growth factor receptor complexes and increases its interaction with RAB5 (a small GTPase that is typically associated with early endosomes). RAB5 has been demonstrated to activate vacuolar protein sorting 34 and the modulation of ATG5-ATG12 conjugation and autophagosome synthesis (Cheung and Ip, 2011; Dou et al., 2013) . mTORC1 blocks autophagy at the protein level and directly phosphorylates and inhibits the key components of ULK1/ULK2 complex. Also, by promoting the sequestration of transcription factor EB (TFEB) in the cytosol, it modulates autophagy at the transcriptional level (Hosokawa et al., 2009 ). The activation of TFEB is regulated by mTORC1 and contributes to synchronize the two major cellular degradative systems: autophagy and lysosomes by the up-regulation of several proteins implicated in the formation of autophagosomes as well as proteins required for the fusion between autophagosomes and lysosomes (Settembre et al., 2011) . Also, mTORC1 regulates TFE3 and ZKSCAN3, which are the positive and negative regulators of lysosomal biogenesis and autophagy, respectively (Chauhan et al., 2013; Martina et al., 2014) .
Additional molecules involved in macroautophagy regulation include 5′-AMP-activated protein kinase (AMPK; Grotemeier et al., 2010) and death-associated protein kinase (DAPK; Eisenberg-Lerner and Kimchi, 2012). The activation of AMPK decreases mTOR signaling activity to facilitate autophagy and promotes the lysosomal degradation of Aβ. Additionally, an increase in cytosolic Ca Ca 2+ /CaM-dependent protein kinase kinase β (CaMKKβ)-mediated activation of AMPK (Grotemeier et al., 2010; Cai et al., 2012) . DAPK is a positive mediator of cell death and a bona fide tumor suppressor. Oxidative stress induces DAPK activation, and under these stress conditions, DAPK activates protein kinase D, which induces the formation of both autophagosomes and autolysosomes through phosphorylation (Shoval et al., 2011; Eisenberg-Lerner and Kimchi, 2012) .
mTOR-independent signaling pathway
Although the canonical mTOR-dependent autophagy pathway is the most well studied, autophagy can be initiated by mTOR-independent pathways and can be mediated through noncanonical signaling events as well. Here, we will highlight a few examples of these alternative pathways.
Ca 2+ signaling has been linked to canonical and noncanonical, mTOR-independent autophagy (Cárdenas and Foskett, 2012; Decuypere et al., 2013) . Ca 2+ signals mediated by IP3 receptor were reported to inhibit autophagy (Criollo et al., 2007; Khan and Joseph, 2010 ). In contrast, an increase in cytosolic Ca 2+ enhanced autophagy (Wang et al., 2008; Vingtdeux et al., 2010) . Li + has also been reported to stimulate autophagy in an mTORindependent manner by inhibiting inositol monophosphatase. Li + activation of autophagy could be reversed by manipulations that raised cytoplasmic IP3 levels, implicating phosphatidylinositol signaling in the regulation of autophagy. Importantly, Li + was without effect on mTORC1 activity, suggesting that the phosphatidylinositol regulation of autophagy was mediated by a noncanonical pathway that operated additively and independently of mTOR (Cárdenas and Foskett, 2012) . ATG5 and ATG7 are believed to be essential genes for autophagy. However, Nishida et al. (2009) showed that mouse cells lacking ATG5 or ATG7 were still able to form autophagosomes/ autolysosomes resulting in autophagy-mediated protein degradation when subjected to certain stressors. Interestingly, the formation of LC3-II by LC3 lipidation did not occur during this process. This alternative process of autophagy was regulated by several autophagic proteins, including ULK1 and Beclin1. Additionally, unlike conventional autophagy, autophagosomes seemed to be generated in an RAB9-dependent manner by the fusion of isolation membranes with vesicles derived from the trans-Golgi and late endosomes (Nishida et al., 2009; Shimizu et al., 2010) . Trehalose, a disaccharide present in many nonmammalian species, has been shown to activate autophagy in an mTOR-independent manner (Sarkar et al., 2007) . In vivo studies have provided evidence that trehalose reduced pathology in a tauopathy mouse model (Schaeffer and Goedert, 2012) and in an amyotrophic lateral sclerosis mouse model where mutant SOD1 is expressed (Chen et al., 2014) . Interestingly, in the ALS mouse model where trehalose had beneficial effects, rapamycin, a classic activator of mTOR-dependent autophagy, actually accelerated motor neuron degeneration and shortened the lifespan of the mice (Zhang et al., 2011) . These studies suggest that, in addition to increasing autophagy, rapamycin likely affects other signaling pathways that may negatively impact neuronal survival, a caveat that needs to be considered when pursuing therapeutic strategies that are directed toward increasing autophagy (Zhang et al., 2011) .
Presenilins as autophagy modulators
Presenilin 1 (PS1) and 2 are multipass membrane proteins that serve as the catalytic center of γ-secretase, which mediates the intramembrane cleavage of more than 20 known substrates, including amyloid precursor protein (APP). These ubiquitous transmembrane proteins have diverse biological roles in the Wnt signaling pathway, calcium channel regulation, cell adhesion, apoptosis, neurite outgrowth, and synaptic plasticity (Chapman et al., 1999; Wan et al., 2014 ; reviewed by Zheng and Koo, 2011) . There is now evidence that presenilins may also play a role in mediating autophagy. The knockdown of presenilins shows an inefficient clearance of longlived proteins. It was also shown that γ-secretase inhibitors do not adversely impact autophagy, suggesting that the role of presenilin in autophagy is independent of γ-secretase activity (Neely et al., 2011) . Wilson et al. found that autophagy-lysosomes increase and selectively accumulate α-and β-synuclein in PS1 -/-neurons, implicating PS1 deficiencies in the mechanisms of α-and β-synuclein trafficking and degradation, which could play a role in α-synuclein lesions in neurodegenerative diseases such as familial AD (Wilson et al., 2004 ) and Parkinson's disease (Stefanis, 2012) . Lee et al. (2010) reported that the loss of PS1 activity leads to impairments in lysosomal function as a consequence of not properly acidified lysosomes, caused by the failed maturation of the proton translocating the V0a1 subunit of the vacuolar (H + )-ATPase and targeting to the lysosome. Their finding of impaired autolysosomes in PS1-deficient cells was consistent with other studies (Esselens et al., 2004; Wilson et al., 2004; Neely et al., 2011; Dobrowolski et al., 2012) . Dobrowolski et al. confirmed the LysoTracker findings of their study (Dobrowolski et al., 2012 ). However, not all studies are in agreement; for example, Neely et al. did not observe a deficit in lysosomal acidification in presenilin doubleknockout (KO) mouse embryonic fibroblast cells and PS1 KO primary neurons using LysoTracker Red (Neely et al., 2011) . Recent studies emphasize that LysoTracker is not a substitute for the direct measurement of lysosomal acidification (Wolfe et al., 2013) . Above all, lysosome acidification deficits detected by the direct measurement of lysosome pH (Wolfe et al., 2013; Coffey et al., 2014) confirmed the earlier findings of Lee et al. (2010) . Zhang et al. reexamined these issues in mammalian cells and in brains of mice lacking both PS1 and PS2 as well as just PS1 and have been unable to find evidence that the turnover of autophagic substrates, vesicle pH, V0a1 maturation, or lysosome function is altered compared to wild-type counterparts. According to their transcriptome studies, using presenilin conditional KO mice, they concluded that presenilin has a role in regulating lysosomal biogenesis but not in cellular autophagosomal regulation (Zhang et al., 2012) . They could not find changes reported by others because the conditional partial deletion of presenilin, specifically in neurons, resulted in the measurement of elements that are present in all cells, including the more abundant glia that may not be a sensitive approach to detecting changes in a subpopulation of affected neurons. Several potential technical issues that may be responsible for discrepancies between these recent studies and the experiments of Lee et al. (2010 Lee et al. ( , 2013 are using different methods to measure pH and performing the biochemical analysis of the V0a1 N-glycosylation state and subcellular localization using different cellular sources. Nonetheless, as a whole, the evidence indicates that presenilins likely play a role in mediating degradative processes, although further studies are required to clearly define the mechanisms by which presenilins affect these processes in these different cellular contexts.
Tung et al. found that cells deficient in PS1 exhibit reduced levels of p62 protein, which is a cargo-receptor shuttling τ for degradation. The down-regulation of PS1 mediated through an Akt/AP-1 pathway led to a significant decrease in both the protein and mRNA transcript of p62, concomitant with attenuated p62 promoter activity. Their study suggests a novel function for PS1 in modulating p62 expression to control the proteostasis of τ (Tung et al., 2014) .
APP processing and autophagic dysfunction
As a result of aging and metabolic or oxidative stress, indigestible or incompletely degraded materials accumulate in a family of mature lysosomal compartments, which include dense bodies, multivesicular bodies, and AVs (Cataldo et al., 1996; Steele et al., 2013) . AVs contain the components for Aβ generation, APP, and its processing enzymes, BACE and presenilin (Yu et al., 2004 (Yu et al., , 2005 .
The deficiency of Beclin1 in cultured neurons and transgenic mice results in increases in APP, Aβ, and the C-terminal fragment, whereas its overexpression reduces the accumulation of Aβ (Pickford et al., 2008; Jaeger et al., 2010; Salminen et al., 2013) . Beclin1 levels are reduced in affected gray matter of patients with early stages of AD (Pickford et al., 2008) . In transgenic mice that express human APP, the genetic reduction of Beclin1 expression increased intraneuronal Aβ accumulation, extracellular Aβ deposition, and neurodegeneration. It also caused microglial changes and profound neuronal ultrastructural abnormalities. The administration of a lentiviral vector expressing Beclin1 reduced both intracellular and extracellular amyloid pathology in APP transgenic mice. From these results, it was concluded that Beclin1 deficiency disrupts neuronal autophagy, impairs AV clearance by lysosomes, modulates APP metabolism, and promotes neurodegeneration in the mice (Pickford et al., 2008) .
Additionally, Aβ could be a regulator of autophagy. Intracellular Aβ could modulate this process by an Aktdependent pathway, RAGE-calcium-CaMKKβ-AMPK pathway, or the induction of mitochondrial reactive oxygen species generation and thus act as an intrinsic checkpoint of its own homeostasis (Hayashi et al., 2009; Lipinski et al., 2010; Son et al., 2012) .
Several studies determined autophagy as a potential therapeutic target to ameliorate neuronal pathogenesis in AD.
Rapamycin, an mTOR inhibitor and an autophagy inducer, is able to reduce Aβ and τ pathology and improve cognition (Spilman et al., 2010; Cai and Yan, 2013) , only when treatment begins before the onset of widespread plaque and tangle accumulation (Majumder et al., 2011) . Also, autophagy induction is necessary for the effects of rapamycin on Aβ (Caccamo et al., 2010) .
Lysosomal proteases play crucial roles in regulating and executing several steps in the autophagic pathway. The cathepsin lysosomal acidic proteases participate directly in lysosomal substrate clearance by degrading vesicular content (Kaminskyy and Zhivotovsky, 2012) . The genetic ablation of cystatin B or treatment with lysosomal protease inhibitors enhanced lysosomal activities and ameliorated amyloid pathologies and memory deficits in an AD mouse model (Felbor et al., 2002; Yang et al., 2011) . These data are consistent with the findings of Lee et al. (2010) that indicted impaired fusion between autophagosomes and lysosomes during the autophagic process and acidification in AD.
Steele et al. provided evidence that, in cultured cells, the antihistamine latrepirdine (Dimebon) stimulated mTOR-and ATG5-dependent autophagy. The chronic administration of latrepirdine to TgCRND8 (APP K670M, N671L, and V717F) attenuated the behavioral deficits and reduced Aβ neuropathology (Steele et al., 2013) . Their work in the current article supports the notion of Oddo et al. through evidence that autophagic failure occurs as a delayed pathology following the deposition of Aβ in a mouse model with intact murine PS1. Nonetheless, latrepirdine failed in phase III clinical trials as a treatment for AD (Sweetlove, 2012) .
Zhu et al. reported that arctigenin (a natural product from Arctium lappa L.) can both inhibit Aβ production by suppressing BACE1 expression and promote Aβ clearance by enhancing autophagy through mTOR inhibition and AMPK/Raptor pathway activation in cells and APP/ PS1 transgenic AD model mice. In this study, arctigenin treatment of the APP/PS1 transgenic mice significantly decreased senile plaques and efficiently reduced memory impairment . This might be the first reported natural product able to both inhibit Aβ production and promote its clearance.
Recently, Shin et al. (2014) investigated whether mesenchymal stem cells (MSCs) could enhance autophagy and therefore exert a neuroprotective effect through the modulation of Aβ clearance in Aβ-treated neuronal cells. The administration of MSC to Aβ-treated animals up-regulated BECN1/Beclin1 expression and significantly increased autophagosome induction, maturation of late AVs, and fusion with lysosomes in addition to significantly reducing Aβ levels in the hippocampus of Aβ-treated mice, concomitant with the increased survival of hippocampal neurons. Two other studies showed that transplantation of human umbilical cord-derived MSCs activates M2-like microglia, which associate with improved cognitive function and Aβ deposition reduction in the AβPP/PS1 transgenic AD mouse model (Darlington et al., 2012; Yang et al., 2013) . Figure 1 addresses some potential therapies and their site of action.
The aforementioned information suggests that we need therapeutic approaches that can enhance lysosomal activity and/or autophagosome/lysosome fusion, besides targeting the autophagic pathway before the onset of autophagic or lysosomal failure (Lee et al., 2010; Majumder et al., 2011) . Additionally, agents with dual functional activities in both Aβ production inhibition and upgrading its clearance might demonstrate more potent anti-AD properties .
τ and autophagic dysfunction
The two major pathways involved in τ metabolism under physiological and pathological conditions are the autophagy-lysosome system and ubiquitin-proteasome system (UPS) (Rubinsztein, 2006; Kirkin et al., 2009b) . For a long time, UPS was considered as a critical route for the degradation of short-lived nuclear and cytosolic proteins such as τ; however, recently, it has been well established that τ can be cleared by autophagy (Rubinsztein, 2006 ; for a review, see Chesser et al., 2013) . Autophagy, but not the UPS, can degrade protein aggregates (Rubinsztein, 2006) . The impairment of both pathways has been described in AD (Keck et al., 2003; Nixon and Yang, 2011) .
There are reports that have demonstrated UPS as a principal τ degradation system (David et al., 2002; Petrucelli et al., 2004; Zhang et al., 2005; Dickey et al., 2007) . Even so, they all investigated overexpressed τ in cell lines instead of endogenous τ in primary neurons. There is evidence that endogenous τ and its overexpressed form undergo different degradation pathways (Luo et al., 2007) .
In an effort to elucidate the importance of autophagic degradation of τ, several groups conducted studies in different cell systems including neuronal cell lines (Berger et al., 2006; Hamano et al., 2008; Wang et al., 2009; Dolan and Johnson, 2010; Krüger et al., 2012) . Different τ fragments might be degraded through distinct autophagic pathways; the full-length molecule is preferentially degraded through macroautophagy, whereas τRDΔK280 (a truncated τ containing pro-aggregated repeat domains that function as a seed for initiating τ aggregate formation) is translocated to lysosomes through CMA machinery (Wang et al., 2009 ). There are two CMA targeting motifs in the fourth repeat domain (336QVEVK340 and 347KDRVQ351) of τ, which are recognized by Hsc70 and delivered to the lysosomal LAMP-2A receptor (Wang et al., 2010) . Another caspase-cleaved τ (τΔC) is present in AD brains and more tending to aggregate and induce neurotoxicity than the natural one. This molecule is appeared to be preferentially degraded through autophagy in a faster turnover rate than the full-length τ (Dolan and Johnson, 2010) . The clearance of soluble τ species is likely to involve selective autophagy adaptor proteins to target τ to the autophagic machinery. Recent studies have provided evidence that NDP52 acts as an autophagy adaptor for τ in neurons facilitating τ degradation by autophagy (Jo et al., 2014) . The treatment of primary neurons with trehalose resulted in a reduction in τ levels via autophagy (Krüger et al., 2012) . In this report, the UPS is inhibited by the application of proteasome inhibitor MG132 and epoxomycin. The results suggested that UPS plays no major role in τ degradation in primary neurons.
Studies from animal models also provide evidence that autophagy contributes to the clearance of τ (Congdon et al., 2012; Schaeffer and Goedert, 2012; Caccamo et al., 2013) . The TSC1 and TSC2 are negative regulators of mTOR, and in TSC2 +/-mice, endogenous mouse τ levels and phosphorylation are increased. Further in P301LS mice, treatment with rapamycin ameliorated τ pathology and the associated behavioral deficits, indicating a role for autophagy in modulating τ levels (Caccamo et al., 2013) . Treatment of mice that overexpress a mutant form of τ (P301S) with trehalose resulted in increased indicators of autophagy in the brain concurrent with a decrease in the number of neurons containing τ inclusions as well as decrease in the amount of insoluble τ (Schaeffer and Goedert, 2012) .
Methylene blue (MB), a phenothiazine derivate, was distinguished as an inhibitor of τ aggregation in vitro (Wischik et al., 1996) . It reduced the levels of 12-kDa τ, Aβ oligomer levels, and amyloid deposits in mouse models (Necula et al., 2007; Harrington et al., 2008; Medina et al., 2011) . MB was recently tested in a phase II clinical trial for AD and has shown encouraging results, as significant improvement in cognitive functions was reported for patients on MB compared to patients on placebo (Wischik et al., 2008) . Its mechanisms of action are still unclear and possibly depend on the active concentration. At micromolar doses, it reduces τ aggregates by the direct prevention of τ-τ binding (Wischik et al., 1996) . A high concentration modulates Hsp70 activity, which correlates with the reduction of τ in cells and animal models (Jinwal et al., 2009; O'Leary et al., 2010) . Administration of MB in a wide range of doses resulted in increased autophagy via mTOR signaling pathway and attenuated τ pathology, in primary neurons and JNPL3 mice, which express P301L-τ (Congdon et al., 2012) . These and other studies indicate that the deficits in autophagy, which occur in AD, likely contribute to the accumulation of τ (Chesser et al., 2013) ; therefore, approaches that increase autophagy should attenuate τ accumulation.
Concluding remarks
The deregulation of autophagy impairs neuronal homeostasis and the balance of energy and nutrient homeostasis, which likely contribute to AD pathogenic processes. In the past decade, there has been a surge in autophagy research, which has significantly increased our understanding of the pathways and mechanisms involved in mediating autophagy (Figure 1) . However, our understanding is far from complete and there is still much to learn about autophagy and its role in AD. Nonetheless, it appears evident that the therapeutic strategies that enhance autophagy have the potential to be beneficial in AD.
